Analysts Set Expectations for OLMA FY2025 Earnings

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Research analysts at HC Wainwright issued their FY2025 EPS estimates for shares of Olema Pharmaceuticals in a report released on Tuesday, November 11th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($1.91) per share for the year. HC Wainwright currently has a “Buy” rating and a $28.00 target price on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals’ Q4 2025 earnings at ($0.55) EPS, Q1 2026 earnings at ($0.58) EPS, Q2 2026 earnings at ($0.61) EPS, Q3 2026 earnings at ($0.65) EPS, Q4 2026 earnings at ($0.69) EPS and FY2026 earnings at ($2.53) EPS.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.05).

A number of other research firms have also commented on OLMA. Citigroup raised their price objective on shares of Olema Pharmaceuticals from $20.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, August 12th. Zacks Research upgraded shares of Olema Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 9th. JPMorgan Chase & Co. upped their target price on Olema Pharmaceuticals from $28.00 to $29.00 and gave the stock an “overweight” rating in a research report on Thursday, August 14th. Oppenheimer restated an “outperform” rating and issued a $22.00 price objective on shares of Olema Pharmaceuticals in a report on Wednesday, September 3rd. Finally, Guggenheim initiated coverage on shares of Olema Pharmaceuticals in a report on Wednesday, October 8th. They set a “buy” rating and a $20.00 price target on the stock. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Olema Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $23.00.

Olema Pharmaceuticals Stock Performance

Shares of NASDAQ OLMA opened at $8.06 on Thursday. Olema Pharmaceuticals has a 52-week low of $2.86 and a 52-week high of $12.70. The stock has a market capitalization of $553.19 million, a price-to-earnings ratio of -4.31 and a beta of 2.07. The company has a quick ratio of 11.09, a current ratio of 8.03 and a debt-to-equity ratio of 0.01. The stock’s fifty day simple moving average is $8.88 and its 200 day simple moving average is $6.27.

Insider Buying and Selling at Olema Pharmaceuticals

In other news, Director Cyrus Harmon sold 3,086 shares of Olema Pharmaceuticals stock in a transaction dated Thursday, September 18th. The shares were sold at an average price of $8.32, for a total transaction of $25,675.52. Following the sale, the director directly owned 117,028 shares in the company, valued at approximately $973,672.96. The trade was a 2.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders have sold 25,000 shares of company stock worth $204,841. 16.36% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. lifted its stake in Olema Pharmaceuticals by 55.4% during the second quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock worth $26,000 after purchasing an additional 2,168 shares during the period. Farther Finance Advisors LLC grew its position in Olema Pharmaceuticals by 602.9% in the second quarter. Farther Finance Advisors LLC now owns 6,839 shares of the company’s stock valued at $29,000 after acquiring an additional 5,866 shares during the period. FNY Investment Advisers LLC raised its stake in Olema Pharmaceuticals by 100.0% during the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock worth $42,000 after acquiring an additional 5,000 shares in the last quarter. Quarry LP bought a new position in shares of Olema Pharmaceuticals during the first quarter valued at $45,000. Finally, American Century Companies Inc. bought a new position in shares of Olema Pharmaceuticals during the second quarter valued at $54,000. Institutional investors own 91.78% of the company’s stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.